Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37387 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL44299 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL2961724 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL3649734 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL37388 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL23723109 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL31338625 | 1.00 | CYP2C9 (0.50) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Water SCHEMBL4393893 | 0.97 | CYP2C9 (0.48) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL30504628 | 0.97 | CYP2C9 (0.48) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| SCHEMBL29825289 | 0.97 | CYP2C9 (0.48) | CYP2C9TSHRPDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573624-B1 | ZWITTERIONICALLY MODIFIED POLYMERS AND HYDROGELS | UNIV CORNELL (US) | 2025-03-19 | — | — | EP | claimed |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | claimed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20230077014-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| CN-104523707-B | Oral controlled release compositions comprising vitamin D compounds and waxy carriers | 欧普科IP 控股II 有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-114469772-A | Anti-inflammatory and relieving composition based on targeted red repairing and preparation method thereof | 广州集妍化妆品科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-11241376-B2 | Skincare composition containing plant extracts and preparation method thereof | ZHEJIANG KANGMANJIA DAILY NECESSITIES CO LTD (CN) | 2022-02-08 | — | — | US | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC | 2021-11-25 | — | — | US | claimed |
| WO-2021158574-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| CN-101785577-B | Method for reducing irritation of papermaking-method tobacco sheets | CHINA TOBACCO HUBEI IND LLC | 2012-02-29 | — | — | CN | claimed |
| WO-2011097261-A1 | STRESS-INDUCED LIPID TRIGGER | SAPPHIRE ENERGY, INC. (US) | 2011-08-11 | — | — | WO | claimed |
| CN-101913791-A | Application of polylol glucoside as cement grinding aid | NANJING YONGNENG MATERIALS CO LTD | 2010-12-15 | — | — | CN | claimed |
| CN-101785577-A | Method for reducing irritation of papermaking-method tobacco sheets | CHINA TOBACCO HUBEI IND LLC | 2010-07-28 | — | — | CN | claimed |
| JP-2002541238-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1183228-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-03-06 | — | — | EP | claimed |
| EP-1127141-A1 | METHOD FOR EXPRESSING RECOMBINANT PROTEINS USING THE EFFECT OF STRESS AND STRESS RESPONSE MECHANISMS IN THE PRESENCE OF COMPATIBLE SOLUTES | Barth, Stefan (DE) | 2001-08-29 | — | — | EP | claimed |
| WO-2000061543-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-19 | — | — | WO | claimed |
| WO-2000028050-A1 | METHOD FOR EXPRESSING RECOMBINANT PROTEINS USING THE EFFECT OF STRESS AND STRESS RESPONSE MECHANISMS IN THE PRESENCE OF COMPATIBLE SOLUTES | BITOP GESELLSCHAFT FÜR BIOTECHNISCHE OPTIMIERUNG MBH (DE) | 2000-05-18 | — | — | WO | claimed |
| EP-0999277-A1 | Method for expression of recombinant proteins through the use of the effects of stress and stress-response mechanisms in the presence of compatible solutes | Barth, Stefan, Dr. rer. nat. (DE) | 2000-05-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR1, CNR2, OPRD1 | CYP2C9 2820/4885TSHR 1176/4885PDE4A 4169/4885 |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | CNR2, CNR1, FAAH | CYP2C9 578/4885TSHR 4477/4885PDE4A 2022/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | CYP2C9 614/4885TSHR 2801/4885PDE4A 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.